STTK 250117 5.00P (STTK250117P5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

STTK250117P5000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 2 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Shattuck Labs Says As Of September 30, 2024, Cash And Cash Equivalents And Investments Were Approximately $90.1M That Is Expected To Fund Its Planned Operations Into 2027, Beyond Results From Its Phase 1 Trial Of SL-325
BenzingaJan 2 07:08 ET
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
GlobeNewswireJan 2 07:00 ET
Shattuck Labs Announces Participation in Upcoming December Conferences
GlobeNewswireNov 25, 2024 07:00 ET
Shattuck Labs Focuses on Promising Antibody Development
TipRanksNov 18, 2024 22:53 ET
TD Cowen Maintains Shattuck Labs(STTK.US) With Buy Rating
Moomoo NewsNov 14, 2024 19:31 ET · Ratings
Shattuck Labs Analyst Ratings
BenzingaNov 14, 2024 13:46 ET · Ratings

Comments

Johnny Mnemonic

Dec 4, 2024 16:45

holding at $1

Johnny Mnemonic

Oct 2, 2024 08:47

quit selling u stupid fks

Jaguar8

Oct 1, 2024 05:50

NEWS

$Shattuck Labs (STTK.US)$
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD...

Trytosaveabit

Jun 26, 2024 16:05

Insider buy

$Shattuck Labs (STTK.US)$ Officer Schreiber Taylor purchased 14,400 shares of common stock on Jun 26, 2024 at an average price of $3.473 for a total value of $50,011.2.

Trytosaveabit

Jun 14, 2024 05:34

Update

$Shattuck Labs (STTK.US)$ Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...